Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway

Journal of Cellular Physiology

Volumn 204, Issue 3, 2005, Pages 964-974

  Wang, Qing ^a   Salman, Hagar ^b   Danilenko, Michael ^b   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; BETA ACTIN; CALCITRIOL; CALCIUM ION; COLLAGENASE; CURCUMIN; EARLY GROWTH RESPONSE FACTOR 1; EBSELEN; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SILIBININ; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1;

ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIOXIDANTS; CALCITRIOL; CALCIUM; CELL CYCLE; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; HL-60 CELLS; HUMANS; IMMEDIATE-EARLY PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; ORGANOSELENIUM COMPOUNDS; PLANTS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS;

EID: 23244454388     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20355     Document Type: Article

References (79)

1. 3. Proc Natl Acad Sci 78:4990-4994.
2. Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23:363-398.
3. Aragones J, Lopez-Rodriguez C, Corbi A, del Arco PG, Lopez-Cabrera M, de Landazuri MO, Redondo JM. 1996. Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage. J Biol Chem 271:10924-10931.
4. Bain J, McLauchlan H, Elliott M, Cohen P. 2003. The specificities of protein kinase inhibitors: An update. Biochem J 371:199-204.
5. Bennett BL, Sasaki DT. Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC. Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci 20:13681-13686.
6. Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS, 2001. Combination of 1alpha,25-dihydroxyvitamin Dn with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res 7:4164-4173.
7. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. 2004. NF-kB and JNK: An intricate affair. Cell Cycle 3:80-85.
8. Byers T, Perry G. 1992. Dietary carotenes, vitamin C, and vitamin E as protective antioxidants in human cancers. Annu Rev Nutr 12:139-159.
9. Chen F, Studzinski GP. 2001. Expression of the neuronal cyclin-dependent kinase 5 activator p35Nck5a in human monocytic cells is associated with differentiation. Blood 97:3763-3767.
10. 3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation. Cancer Res 64:5425-5433.
11. Christy BA, Lau LF, Nathans D. 1988. A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. Proc Natl Acad Sci USA 85:7857-7861.
12. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. 1979. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med 149:969-974.
13. 3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083-1088.
14. 3-relevance for colonic cancer prevention and therapy. Mol Aspects Med 24:459-465.
15. 3 and its analogs. Exp Cell Res 298:339-358.
16. Danilenko M, Wang X, Studzinski GP. 2001. Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. J Natl Cancer Inst 93:1224-1233.
17. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 5:1325-1332.
18. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. 1993. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 90:2419-2422.
19. Davis RJ. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103:239-252.
20. Dawson DA, Masayasu H, Graham DI, Macrae IM. 1995. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett 185:65-69.
21. Degos L, Wang ZY. 2001. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 20:7140-7145.
22. Douer D. 2002. Advances in the treatment of relapsed acute promyelocytic leukemia. Acta Haematol 107:1-17.
23. Eckert RL, Crish JF, Efimova T, Balasubramanian S. 2004. Antioxidants regulate normal human keratinocyte differentiation. Biochem Pharmacol 15:1125-1131.
24. Esposito F, Agosti V, Morrone G, Morra F, Cuomo C, Russo T, Venuta S, Cimino F. 1994. Inhibition of the differentiation of human myeloid cell lines by redox changes induced through glutathione depletion. Biochem J 301:649-653.
25. Farhan H, Wahala K, Cross HS. 2003. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem Mol Biol 84:423-429.
26. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. 1979. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713-733.
27. Gius D, Botero A, Shah S, Curry HA. 1999. Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1. Toxicol Lett 106:93-106.
28. Greenwald P, Kelloff G, Burch-Whitman C, Kramer BS. 1995. Chemoprevention. CA. Cancer J Clin 45:31-49.
29. Guyton KA, Kensler TW, Posner GH. 2001. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 41:421-442.
30. Hansen JB, te Riele H, Kristiansen K. 2004. Novel function of the retinoblastoma protein in fat: Regulation of white versus brown adipocyte differentiation. Cell cycle 3:774-778.
31. Harada T, Morooka T, Ogawa S, Nishida E. 2001. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr-1. Nat Cell Biol 3:453-459.
32. Heasley LE, Storey B, Fanger GR, Butterfield L, Zamarripa J, Blumberg D, Maue RA. 1996. GTPase-deficient G alpha 16 and G alpha q induce PC12 cell differentiation and persistent activation of cJun NH2-terminal kinases. Mol Cell Biol 16:648-656.
33. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. 1988. Use of all-trans retinoid acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572.
34. 3-induced monocytic differentiation. Cancer Res 64:370-377.
35. 3. and all-trans retinoic acid-induced differentiation of human promvelocytic leukemia HL-60 cells. Eur J Pharmacol 420:83-90.
36. Kang SN, Lee MH, Kirn KM, Cho D, Kim TS. 2001b. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: Involvement of protein kinase C. Biochem Pharmaco 16:1487-1495.
37. 3 and its fluorinated analogues. Cancer Res 44:5624-5628.
38. Krishnan AV, Peehl DM, Feldman D. 2003. The role of vitamin D in prostate cancer. Recent Results Cancer Res 164:205-221.
39. Krishnaraju K, Hoffman B, Liebermann DA. 2001. Early growth response gene 1 stimulates development of hematopoietic progenitor cells along the macrophage lineage at the expense of the granulocyte and erythroid lineages. Blood 1:1298-1305.
40. Lee LF, Li G, Templeton DJ, Ting JP. 1998. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253-28260.
41. Leniaire P, Revelant O, Bravo R, Charnay P. 1988. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc Natl Acad Sci USA 85:4691-4695.
42. Lim RW, Varnum BC, Herschman HR. 1987. Cloning of tetradecanoyl phorbol ester-induced 'primary response' sequences and their expression in density-arrested Swiss 3T3 cells and a TPA non-proliferative variant. Oncogene. 1:263-270.
43. 3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol Res 9:19-29.
44. Mace K, Offord EA, Harris CC, Pfeifer AM. 1998. Development of in vitro models for cellular and molecular studies in toxicology and chemoprevention. Arch Toxicol Suppl. 20:227-236.
45. 2+ signaling in normal human gastric mucous epithelial cells. Am J Physiol Gastrointest Liver Physiol 285:G163-G176.
46. Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE. 1996. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci 93:12908-12913.
47. Milbrandt J. 1987. A nerve growth factor-induced gene encodes a possible transeriptional regulatory factor. Science 238:797-799.
48. 3 and dexamethasone in inducing differentiation of mouse mveloid leukemia cells. Arch Biochem Biophys 227:379-385.
49. Nagata Y, Todokoro K. 1999. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 94:853-863.
50. Nguyen HQ, Hoffman-Liebermann B, Liebermann DA. 1993. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell 29:197-209.
51. O'Kelly J, Koefner HP. 2003. Vitamin D analogs and breast cancer. Recent Results Cancer Res 164:333-348.
52. Owuor ED, Kong AN. 2002. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64:765-770.
53. Peehl DM, Seto E, Feldman D. 2001. Rationale for combination ketoconazole vitamin D treatment of prostate cancer. J Urol 58:123-126.
54. Peehl DM, Seto E, Hsu JY, Feldman D. 2002. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 168:1583-1588.
55. 3 in lipiodol for the treatment of hepatocellular carcinoma: Cellular, animal and clinical studies. J Steroid Biochem Mol Biol 89:513-518.
56. 3 derivative, alone or in association with dexamethasone. Blood 88:4646-4659.
57. Rovera G, O'Brien TG, Diamond L. 1979. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204:868-870.
58. Sabapathy K, Wagner EF. 2004. JNK2: A negative regulator of cellular proliferation. Cell Cycle 3:193-196.
59. Sharma Y, Agarwal C, Singh AK, Agarwal R. 2001. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 30:224-236.
60. Sharoni Y, Stahl W, Danilenko M, Levy J. 2003. The anticancer activity of carotenoids: from human studies to cellular processes and gene regulation. In: Krinsky N, Mayne ST, Sies H, editors. Carotenoids in health and disease. New York (NY): Marcel Dekker. pp 165-196.
61. Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W, Radzikowski C. 2001. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 21:1925-1929.
62. Spike BT, Macleod KF. 2005. The Rb tumor suppressor in stress responses and hematopoietic homeostasis. Cell Cycle 4:181-184.
63. Sporn MB, Suh N. 2002. Chemoprevention: An essential approach to controlling cancer. Nat Rev Cancer 2:537-543.
64. 3 andretinoic acid. Nutr Cancer 41:135-144.
65. Stewart LV, Weigel NL. 2004. Vitamin D and prostate cancer. Exp Biol Med 229:277-284.
66. 3. Cancer Res 45:3898-3905.
67. 3-resistant HL 60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. Cancer Res 56:5513-5521.
68. Thiel G, Cibelli G. 2002. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193:287-292.
69. Torres M. 2003. Mitogen-activated protein kinase pathways in redox signaling. Front Biosci 8:d369-d391.
70. Valenzuela A, Sanhueza J, Nieto S. 2003. Cholesterol oxidation: Health hazard and the role of antioxidants in prevention. Biol Res 36:291-302.
71. 3-induced differentiation of HL60 cells. J Cell Biochem 80:471-482.
72. 3. J Natl Cancer Inst 89:1199-1206.
73. 3. J Cell Biochem 89:1087-1101.
74. 3receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 83:85-92.
75. Wenzel U, Schoberl K, Lohner K, Daniel H. 2005. Activation of mitochondrial lactate uptake by flavone induces apoptosis in human colon cancer cells. J Cell Physiol 202:379-390.
76. 3 analogue, in a phase I study of patients with advanced malignancies. Invest New Drugs 21:445-452.
77. Wisdom R. 1999. AP-1: One switch for many signals. Exp Cell Res 253:180-185.
78. 3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 90:134-141.
79. 3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific. J Steroid Biochem Mol Biol 57:197-202.